ArticleFrontiers in medicine2026
Regularization via gradient attribution for multiple sclerosis lesion segmentation.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Accurate segmentation of Multiple Sclerosis (MS) lesions from Magnetic Resonance Imaging (MRI) is fundamental for robust disease monitoring and for the evaluation of therapeutic efficacy. Within Internet of Medical Things (IoMT)-based diagnostic infrastructures, where deep learning models serve as autonomous computational nodes embedded in interconnected clinical workflows, ensuring reliable lesion detection without continuous human supervision is a critical operational and clinical requirement. A persistent methodological challenge is the pronounced class imbalance characteristic of MS neuroimaging datasets. This imbalance causes conventional loss functions to systematically miss small lesions, thereby directly compromising the utility of automated image analysis as an instrument for precision medicine. Methods: This work proposes the Regularization via Gradient Attribution (RGA) framework, a module that leverages gradient-based eXplainable Artificial Intelligence (XAI) attribution maps as active supervisory signals during training. Instead of constraining the learning process exclusively at the prediction-output level, RGA imposes additional penalties on the network when false-negative lesion regions have low internal attribution and when false-positive healthy-tissue regions exhibit elevated attribution. The framework is architecturally agnostic, compatible with both convolutional and transformer-based backbone networks, and accommodating arbitrary spatial attribution techniques. RGA was evaluated on two public MS lesion segmentation datasets, MSLesSeg and 3D-MR-MS, using three backbones (nnU-Net, UNETR, TransBTS) and two XAI methods (LayerCAM, Integrated Gradients) in 5-fold cross-validation. Results: On both datasets, RGA consistently improved DSC, TPR, and LTPR over the baselines. The best configuration, nnU-Net + RGA achieved a DSC of 0.7056 on MSLesSeg and 0.7466 on 3D-MR-MS, with RGA yielding the highest DSC for all backbones. Qualitative analyses further substantiate these findings by demonstrating a marked reduction in missed-lesion regions across all model architectures, without a corresponding substantial increase in false-positive predictions. Discussion: By jointly providing high lesion-level detection completeness, model interpretability, and zero additional inference-time computational cost, RGA represents a methodologically grounded approach compatible with IoMT-oriented precision-medicine pipelines, while requiring dedicated deployment validation before clinical or edge-device implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.